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The procurement of induced pluripotent stem cells, or IPS cells, from adult diﬀerentiated animal cells has the potential to
revolutionize future medicine, where reprogrammed IPS cells may be used to repair disease-aﬀected tissues on demand. The
potential of IPS cell technology is tremendous, but it will be essential to improve the methodologies for IPS cell generation and to
precisely evaluate each clone and subclone of IPS cells for their safety and eﬃcacy. Additionally, the current state of knowledge on
IPS cells advises that research on their regenerative properties is carried out in appropriate tissue and organ systems that permit
a safe assessment of the long-term behavior of these reprogrammed cells. In the present paper, we discuss the mechanisms of cell
reprogramming, current technical limitations of IPS cells for their use in human tissue engineering, and possibilities to overcome
them in the particular case of dental regeneration.
1. CellDedifferentiationandPluripotency
Cellular dediﬀerentiation underlies important issues in biol-
ogy, such as tissue regeneration and cloning, and signiﬁes the
withdrawal of cells from a given diﬀerentiated state into a
stem-cell-likestatethatconferspluripotency.Pluripotencyin
vivo pertains to the cells of early embryos that can generate
all of the tissues in the organism. Embryonic stem cells
(ESC)arepreimplantationembryo-derivedcellshavingthree
properties: self-renewal, pluripotency, and primary chimera
formation [1]. ES cells represent invaluable tools for research
intothemechanismoftissueformation.Invitropluripotency
may be maintained in ES cells, which are harvested from
the inner cell mass of the blastocyst stage embryo. ES cells
have demonstrated longevity in culture by maintaining their
undiﬀerentiated state for at least 80 passages. Moreover,
if ES cells are cultured with the appropriate nutrients at
their disposal, these cells can potentially give rise to all cell
types of the body, including pluripotent germinal cells, and
their oﬀspring can become integrated in a tissue, adopting
the character and behavior of the cells in this new tissue
environment. However, there are also signiﬁcant problems
associated with the use of human ES cells.
(i) Their obtention involves manipulation of human
embryos and therefore serious legal and ethical issues
[2].
(ii) If the transplanted cells diﬀer genetically from the
cells of the patient, the immune system of the latter
may reject and destroy these cells and the patients
would be on life-long immunosuppressants.
(iii) Pluripotent stem cells (SCs) present a safety concern
because of their potential to form tumours. When
these cells are transplanted in the undiﬀerentiated
state, they form teratomas, tumours derived from all
three germ layers. Currently, the only way to ensure
that teratomas do not form is to diﬀerentiate the ES
cells, enrich for the desired cell type, and screen for
the presence of undiﬀerentiated cells [3].
The ﬁrst two of these problems could be avoided using
dediﬀerentiation of somatic cells as a means to obtain2 Stem Cells International
autologous “patient speciﬁc” pluripotent stem cell lines.
The capacity for dediﬀerentiation is retained in mammalian
somatic cells, and the reprogramming technology has pro-
vided two strategies for the generation of pluripotent SCs
from adult diﬀerentiated cells.
(1) The denominated somatic cell nuclear transfer
(SCNT) also called “therapeutic cloning” or nuclear
cloning (NC): one hallmark in this ﬁeld of research
took place in 1996 with the birth of Dolly, the cloned
sheep conceived by transfer of an adult diﬀerentiated
cell nucleus to an enucleated unfertilized oocyte [4].
This groundbreaking discovery made evident that
even somatic highly diﬀerentiated cells retain the
intrinsic ability to revert to a zygote state and thus
provide a potentially inexhaustible source of ES cells.
(2) The generation of pluripotent cells from diﬀerenti-
ated reprogrammed animal cells, known as induced
pluripotent SCs, or IPS cells: one decade after the
birth of Dolly, another decisive discovery brought the
advent of IPS cells by transgenic expression of merely
four transcription factors in adult somatic mouse
cells, namely, Oct3/4, Sox2, Klf4, and c-myc [5]. This
protocol also worked with adult human cells, using
OCT3/4, SOX2, KLF4, and c-MYC [6]o rOCT-4,
SOX-2, LIN28, and NANOG [7].
Somatic cell nuclear transfer (SCNT) entails the removal
of an oocyte nucleus followed by its replacement with
a nucleus derived from an adult somatic cell [8]. SCNT
has limitations; in addition to the serious ethical issues
surrounding the cloning of human embryos created for
research [9], the scarcity of fresh donated mature human
metaphase-II oocytes of high quality available for research
is a signiﬁcant obstacle [10]. Currently, the eﬃciency of
the overall cloning process is quite low as the majority
of embryos derived from animal cloning do not survive
after implantation [11]. At present, the medical applications
of SCNT have been halted on account of the ineﬃcacy
of the process, the lack of knowledge of the underlying
mechanism, and ethical concerns [12]. Nevertheless, nuclear
transfer has shown that all genes required to create an entire
organism are present in the nucleus of the diﬀerentiated
cell and can be activated on exposure to reprogramming
factors present in the oocyte [13]. In addition, SCNT is
a powerful tool to probe the developmental potential of
a cell, and the major conclusion from these ﬁndings was
that development imposes reversible epigenetic rather than
irreversible genetics changes on the genome during cellular
diﬀerentiation[14].However,generationofembryosdirectly
from embryonic stem cells by tetraploid embryo comple-
mentation has become a popular means as an alternative to
SCNT.
Somatic cells can be reprogrammed by fusion with
ES cells, and Takahashi and Yamanaka concluded that ES
cells contain factors that induce pluripotency, and these
factors were also likely involved in the maintenance of
pluripotency in ES cells. Based on this hypothesis, they
showed that ectopic expression of deﬁned transcription
factors was suﬃcient to reprogram mouse embryonic ﬁbrob-
lasts and adult ﬁbroblasts to pluripotent ES-like cells after
retroviral-mediated transduction of the four transcription
factors Oct3/4, Sox2, c-myc, and Klf-4, under ES culture
conditions [5]. These cells, designated IPS cells, exhibit
the morphology and growth properties of ES cells and
express ES marker genes. Subcutaneous transplantation of
IPS cells in nude mice resulted in teratomas. Injection of
iPS cells into blastocyst contributes to chimaeras. IPS cells
showed unlimited proliferation in vitro maintaining their
pluripotency. Overexpression of the four factors generated
cells capable of forming adult chimaeras and generating
functional germ cells [15–18]. Human IPS cells, produced by
expression of either Oct-4, Sox-2, c-myc, and Klf-4 or Oct-4,
Sox-2, Nanog, and Lin-28, are remarkably similar to human
ES cells [19]. However, controversy exists with regard to the
diﬀerentialgeneexpressionproﬁles(geneticsignatures)inES
and IPS cells [20, 21]. Consistent with this, IPS cells show
attenuated potential diﬀerentiation in comparison to ES cells
[22, 23].
A major limitation of reprogramming strategies is the
u s eo fp o t e n t i a l l yh a r m f u lg e n o m ei n t e g r a t i n gv i r u s e st o
deliver reprogramming factor transgenes. Most IPS cells
are prepared by viral vectors, such as retrovirus [5]a n d
lentivirus [24], that integrate the reprogramming factors
into host genomes, increasing the risk of tumor formation.
The residual presence of integrated transgenes following
the derivation of IPS cells is highly undesirable. The four
factors used to induce reprogramming are strictly speaking
oncogenes,thusimplyingariskoftransformationtoacancer
phenotype. There are substantial grounds to state that the
process of nuclear reprogramming by virus-assisted factor
insertion in the cell genome increases the risk of carcinogen-
esis [25]. Supporting this, the eﬃciency of reprogramming
increases largely in cells where the p53 tumor suppressor
geneisknocked-out[26,27].Thishighriskofcarcinogenesis
is largely, but not exclusively, related to the integration of c-
MYC transgenes [28, 29].
Alternative gene factor delivery systems include non-
integrating adenoviruses [30], plasmid transfection [31],
doxycycline-inducible excisable piggyBac (PB) transposon
system [32], and nonintegrating episomal vectors [33].
Anotherdiﬀerentstrategyconsistsofdeliveryofrecombinant
proteins rather than genes into the cells to be reprogrammed
[34, 35]. Others have explored the induction of repro-
gramming by chemical stimulation and screening/selection
of eﬀective small molecules, thus reducing the amount of
factors delivered to cells [36]. Using the latter approach,
there have been successful trials to generate IPS cells with
the introduction of only one reprogramming factor (OCT-
4) in multipotent neural SC [37] and dermal papilla cells
from hair follicles [38]. The four factors that were initially
identiﬁed can now be substituted with diﬀerent factors or
with certain small molecules, but the original ﬁnding—that
a set of factors is required—holds true, and certain key gene
factors such as OCT-4 cannot be omitted.
The possibility to obtain patient-speciﬁc IPS cells has
broughtbighopeontheprospectoffuturetissueengineering
regenerative therapies by cell transplant since these newStem Cells International 3
pluripotent cells circumvent two of the main problems tra-
ditionally associated with the sources of human pluripotent
SCs: the serious ethical issues arising from the need to
manipulate human embryos, and the possibility of rejection
of the transplanted cells by the host immune system.
However, the induction of carcinogenesis remains a pending
threat. The potential of IPS cell technology is tremendous,
but it will be essential to improve the methodologies for
IPS cell generation and to precisely evaluate each clone and
subclone of IPS cells for their safety and eﬃcacy. It will be
necessary to perform a detailed cellular and molecular study
of somatic cells during their progression to pluripotent state
[39]. Many aspects still remain to be clariﬁed, given that the
eﬃciency of the cell reprogramming process is certainly very
low [40].
2. Tissue Engineering and IPS Cells: Deﬁnition
and General Concepts
Tissue engineering aims to generate living tissues that could
be used for the restoration of the function of several organs
[41]. Tissue engineering has progressed from the use of bio-
materials, which may repair or replace diseased or damaged
tissue, to the use of controlled three-dimensional scaﬀolds in
which cells can be seeded before implantation [42]. Organ
shortage and suboptimal prosthetic or biological materials
f o rr e p a i ro rr e p l a c e m e n to fd i s e a s e do rd e s t r o y e dh u m a n
organs and tissues are the main motivation for increasing
research in the emerging ﬁeld of tissue engineering in
regenerative medicine [43–45]. While tissues such as bone
or skin can eﬀectively repair a small injury given suﬃcient
time,manytissuessuchasmyocardium,cartilage,andneural
tissues do not regenerate properly without intervention [46].
The availability of sources of pluripotent SC has
increasedimmenselythepotentialofcelltherapyinmedicine
and opens up new perspectives in the treatment of dis-
eases [47, 48]. IPS cells can proliferate and be induced
to diﬀerentiate to a particular cell type, and the selected
cells can be seeded in a speciﬁc mould or scaﬀold and
cultured in vitro.S c a ﬀolds (natural or synthetic) may be
composed of polymers, metals, ceramics, or composites [49,
50]. Bioreactors are used to grow the cells on the scaﬀolds
until the tissue or the organ is fully developed [41]. The
cells can be expanded in culture and then reimplanted in
the patient [51, 52] (Figure 1). The cells can come from the
same individual (autologous) or the same species but from a
diﬀerent individual (allogeneic) or even can originate from
diﬀerent species (heterologous).
Nevertheless, because of the limitations inherent to the
cellreprogrammingprocess,itisadvisedthatresearchonIPS
cells in the ﬁeld of tissue engineering is carried out in appro-
priate tissue and organ systems that permit a safe assessment
of the long-term behavior of these reprogrammed cells. As
we will discuss in the last part of the paper, the dental system
may constitute a very good choice as a testing ground for IPS
cells applied to tissue engineering, owing to several speciﬁc
features of dental cells and tissues. We will proceed by brieﬂy
describing endogenous sources of dental SC, the process of
IPS cells
Multipotent
stem cells
In vitro
culture
Seeding in scaﬀolds
Figure 1: Basic scheme of tissue engineering. A biopsy is carried
out to extract cells from the patient. These can be endogenous
organ-speciﬁc multipotent SCs, or alternatively they can be adult
diﬀerentiated somatic cells, reprogrammed to IPS cells. SCs are
isolated, expanded and diﬀerentiated to the cell type of interest in
an appropriate culture medium, seeded in a scaﬀold, and cultured
in vitro. At this point, the new tissue is implanted in the patient.
normal tooth development and its associated structures, and
ﬁnally we will discuss how these features may constitute a
decisive advantage to investigate future applications of IPS
cells in full dental regeneration.
3. Are Teeth the New Golden Mine of SC?
Teeth are nonvital organs that, remarkably, have proven to
be a surprisingly rich source of multipotent ectomesenchy-
m a lS C( E M S C ) .T h em a j o r i t yo fl i v ea d u l tt o o t ht i s s u e s
derive from the neural crest, and therefore all dental SCs
considered here are collectively termed EMSCs. Teeth are
easilyamenableforextraction in thedental clinic, precluding
the need of complex chirurgical care and invasive isolation
methods. Owing to their amount and accessibility, dental
tissues constitute one of the most consistent sources of
human SCs that can be found nowadays. Human teeth are
extracted and disposed of by thousands in dental clinics
worldwide, the majority of them corresponding to third-
molars (wisdom teeth) of young patients, which are usually
removed for orthodontic reasons.
There are ﬁve diﬀerent types of dental EMSCs that
have been isolated and characterized: dental pulp SC, or
DPSC [53], SC from human exfoliated deciduous teeth,
or SHED [54], periodontal ligament SC, or PDLSC [55],
SC from the apical papilla, or SCAP [56] ,a n dS Cf r o m
dental follicle [57]. All these display stem cell features
such as multilineage diﬀerentiation potential to various
cell types including odontoblasts, cementoblasts, osteoblasts,
chondroblasts, adipocytes, muscle cells, and neurons [58].
Notably, due to their neural crest origin, dental SCs are
considered to be a good stem cell choice to generate neural
and glial cell derivatives. Some of these cells, such as SHED,
express early immature glial and neuronal cell markers4 Stem Cells International
in basal conditions, even in the absence of neurogenic
stimulation [54].
Very recent research has described a population of OCT-
4+, NANOG+, LIN28+, and SOX-2+ cells in the dental pulp
that is argued to constitute an endogenous dental source
of pluripotent SCs [59]. These cells can be induced to
diﬀerentiate to endoderm and mesoderm cell derivatives. If
thisﬁndinggotconﬁrmedbyotherresearchteamsinthenear
future, the ﬁeld of dental stem cell research will no doubt
receive a deﬁnite boosting. Other tested strategies to obtain
pluripotentcellsoutofdentalcellsconsistofreprogramming
dental multipotent EMSC or adult gingival and periodontal
ﬁbroblasts to IPS. This has been successfully carried out by
diﬀerent research groups [60–62].
4. Potential of the Dental Systemfor IPS
Technology inFullOrganBioengineering
DentalSCshavebeensuccessfullytestedintissueengineering
research, where full generation of dentin pulp complexes
and even whole teeth out of isolated cells (complete organ
restoration) has proven to be possible [63]. The two cell
types that take part in the generation of teeth come from dif-
ferent embryonic origins: surface epithelial (ectoderm) and
ectomesenchymal(neuralcrest).Thosetissuesareprecursors
of the enamel organ and dental papilla, which will generate
tooth enamel and the dentin-pulp complex, respectively.
Tooth development takes place over diﬀerent morphogenetic
stages (placode, bud, cap, bell, appositional) and is governed
through a complex series of epithelial-mesenchymal cellular
inductions. As a consequence of continuous reciprocal sig-
naling, the precursors of ameloblasts and odontoblasts, the
two key mineralizing adult dental cell types, will elongate,
polarize, and diﬀerentiate at the epithelium-mesenchyme
interface. These ameloblastic (enamel producing) and odon-
toblastic(dentinproducing)cellswillterminallydiﬀerentiate
at the late bell-early appositional stage transition, and this
will mark the beginning of secretion and deposition of hard
enamel and dentin tissues, starting by the tooth cusps [64].
Importantly, once the deposition and maturation of
tooth enamel is complete, ameloblastic cells will undergo a
drastic regression, losing their elongated size and polarized
state and mingling with adjacent epithelial cells to form the
so-called “reduced enamel epithelium,” a transient coating
structure that will end up disappearing at the moment of
tooth eruption. The only epithelial cells that will remain in
adult tooth structures are the epithelial cell rests of Malassez
(ECRM), deriving from Hertwig’s epithelial root sheath
(HERS), another transient structure involved in dental root
formation. ECRMs play no known role in the adult tooth
and appear as little cell clusters in the periodontal ligament.
On the contrary, ectomesenchyme-derived odontoblasts and
dental pulp tissues will persist throughout the tooth life well
into adulthood (Figure 2).
De novo generation of fully functional dentin-pulp
complexes and periodontal tissues has been successfully
accomplished by transplantation of endogenous EMSC to
experimental animals, in combination with mineralized
hydroxyapatite/tricalcium phosphate scaﬀold carriers [65].
Transplantedcellseventuallyassimilateandremodelthescaf-
fold to create completely biological structures. Under these
conditions, it is also possible to design a biological tooth
root that supports the placement of a synthetic tooth crown,
as shown by elegant studies [66]. With improvements and
adaptations of this technique, in the future it may be possible
to replace synthetic implants by biocompatible engineered
tooth root tissues in humans. Therefore, endogenous EMSCs
hold a big potential for their use in regenerative dentistry.
Even more striking was the reported generation of func-
tional mouse teeth generated exclusively from dissociated
dental SCs. In a sound study, Tsuji et al. [67] isolated
dental epithelial cells from E14.5 cap stage mouse teeth and
recombinedthemtogetherwithectomesenchymalDPSCina
collagengel,thuscreatingabioengineeredmolartoothgerm.
Remarkably, the bioengineered tooth proceeded normally
through all the diﬀerent morphogenetic stages and could be
eventually transplanted into the jawbone of a host mouse,
to create a fully functional adult tooth that integrated well
into surrounding tissues, presented a correct occlusion,
supported masticatory forces, could perform orthodontic
movements, was normally innervated, and responded ade-
quately to pain stimuli. This positive experience holds great
promise in the ﬁeld of full dental organ regeneration, which
would no doubt revolutionize future dentistry.
However, obviously much experimentation is required
and major issues need yet to be solved before an approach
like tooth germ engineering by dental stem cell recombina-
tion can be translated to the dental clinic. Probably the most
important limiting factor is the absence of consistent sources
of epithelial SC with odontogenic potential in the adult
humanindividual,toberecombinedwithendogenousdental
mesenchymal SCs. There has been substantial progress in the
identiﬁcation of possible epithelial substitutes, using PDL-
derived ECRM [68], and postnatal oral mucosal epithelial
cells [69]. Both these cell types can be cultured in vitro
and induced to diﬀerentiate to ameloblastic cell lineages.
Another realistic possibility, exclusively for research pur-
poses, would constitute the rodent incisor, which contains
an epithelial stem cell niche [70]. However, although the
sources of endogenous dental epithelial SC seem to be
scarce, an appealing alternative would be to obtain them
from autogenic IPS cells, properly diﬀerentiated in vitro.
Once this step is accomplished, the remaining process
of recombination into collagen scaﬀold matrices, in vitro
organ culture, and in vivo transplantation should not pose
extreme technical diﬃculties. The ﬁnal outcome would be a
fully developed bioengineered human tooth obtained from
dissociated autogenic EMSC and IPS cells, in which the latter
would almost completely disappear after tooth eruption
(Figure 3).
Thus, there are several arguments that point to teeth as
av e r ya t t r a c t i v es y s t e mt ot e s tI P Sc e l l si nac o n t e x to ff u l l
organ restoration therapy.
(i) First, tooth development by epithelial (IPS derived)
and ectomesenchymal (endogenous) autogenic or
allogeneic cell recombination can be performed andStem Cells International 5
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Figure 2: Stages and events of molar tooth development. Tooth morphogenesis is carried out by complex epithelium-ectomesenchyme
interactions. Epithelial cells are depicted in gray and ectomesenchymal cells in red. As a consequence of sequential induction events,
ameloblast (A) and odontoblast (O) cells start to diﬀerentiate at the interface between dental epithelium (de) and dental mesenchyme
(dm) at the end of bell stage. Enamel (E) and dentin (D) tissues are secreted during the appositional stage, when the developing dental
organ appears separated from the oral epithelium (oe). When enamel mineralization is completed, ameloblasts undergo regression, whereas
odontoblasts will be maintained during the whole life of the tooth. The areas covered by squares are represented magniﬁed below. Signaling
centers during tooth morphogenesis are drawn as red circles: dental placode (dp), primary enamel knot (pek), and secondary enamel knot
(sek). pA: preameloblasts; pO: preodontoblasts.
In vitro recombination
Dental pulp
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stem cells
Adult tooth
Diﬀerentiation to
odontogenic
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(1) In vitro culture
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Figure 3: Theoretical design of a dental engineering process involv-
ing IPS cells. Tooth tissues already present well-characterized pop-
ulations of ectomesenchymal SCs, that can generate de novo
a complete dentin-pulp complex and periodontium. The hard
enamel tissue constituting the remaining part of the tooth must
be formed by dental epithelial cells. In this context, autogenic
IPS cells could be used as a source of new dental epithelium,
to be recombined with ectomesenchymal cells, thus creating a
bioengineered tooth germ that can be cultured in vitro and
transplanted to the jawbone/maxillary bone of a recipient host to
form a fully functional tooth. Almost all IPS-derived epithelial cells
will disappear after tooth eruption, as a consequence of normal
dental development.
followed up in vitro during early developmental
stagesuptotwoweeks,thereforepermittingselection
of the most appropriate or best-looking bioengi-
neered teeth before transplant.
(ii) Second, IPS cells in the context of tooth engineering
are mostly needed as a source of dental epithelial
cells and eventually enamel producing ameloblasts.
These epithelial cell derivatives will be present only
transientlyanddisappearaftertootheruptionoccurs,
with the sole exception of ECRM. Therefore, the
risk of IPS-induced tumorigenesis should be greatly
reduced in the dental system.
(iii) Third, it is possible to generate autogenic (patient-
speciﬁc) IPS cells from dental cells and tissues to
minimize the chance of immune rejection.
(iv) Fourth, long-term outcomes of biological teeth can
be readily followed during routine dental and peri-
odontal check-ups, even by visual exploration.
(v) Finally, should complications arise because of the use
of SC or IPS cells (tumorigenic or other), extraction
of the tooth piece can be performed with relative
simplicity, by noninvasive procedures and with no
life-threatening risk to the patient.
At the present time, we have no means to predict
what will be the future of IPS technology to treat human
diseases by cell therapy, but the recently discovered process
of adult cell reprogramming still continues to fascinate the
research community. No doubt that development of safe6 Stem Cells International
nontumorigenicIPScelllineswillhaveagreatdealtodowith
their eventual success [71, 72]. Time will tell whether teeth
will become an important testing ground for applications of
IPS cells in a complex context of tissue regeneration, with
multiple cells of diﬀerent lineages, IPS and host, that will
need to coordinate and communicate with each other. It
seems clear that we will learn a lot about IPS cell integration
on tissues over the next decades.
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